Abstract: The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.

Abstract: The present invention provides compositions comprising a substance of a particle size between 1 ?m and 100 ?m and a solubility in water between 0.0001 g/l and 10 g/l, at least 2 wt % of at least one cellulose based polymer, at least one anionic surfactant, at least one non-ionic surfactant, wherein the non-ionic surfactant is present in an amount of non-ionic surfactant to at least one cellulose based polymer in the range of between 10:1 and 1:10, wherein the ratio of the at least one cellulose based polymer and the at least one non-ionic surfactant together to the substance is between 2:1 to 1:2, and wherein the concentration of the substance of a particle size between 1 ?m and 100 ?m and a solubility in water between 0.0001 g/l and 10 g/l is in the range of 10.1 wt % to 15 wt %. The present invention also provides methods of manufacturing the compositions.

Abstract: The invention relates to substituted S-alaninate derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular vascular disorders, preferably thrombotic or thromboembolic disorders and/or thrombotic or thromboembolic complications.

Abstract: The present invention relates to stable nanosuspensions of methyl {4,6-diamino-2-[5-fluoro-1-(2- fluorobenzyl)-1H-pyrazolo[3,4-b]pyridin-3-yl]pyrimidin-5-yl}carbamate (Vericiguat, compound of formula (I)), processes for preparing the stable nanosuspensions, nanoparticles comprising the compound of formula (I), and pharmaceutical compositions in solid form made from the nanosuspensions.

Abstract: The invention relates to substituted dihydropyrazolo pyrazine carboxamide derivatives and to processes for their preparation, and also to their use for preparing medicaments for the treatment and/or prophylaxis of diseases, in particular cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and diabetes, and also urogenital and ophthalmic disorders.

Abstract: A process for the manufacture of linear, substantially gel free, high cis 1,4 poly(butadiene) comprising polymerization in the presence of (a) a catalyst comprising at least one cobalt compound, at least one organoaluminium compound, and water, and (b) a cycloalkane as main solvent component, and (c) at least one substituted benzene as polymerization regulator of the general formula ##STR1## wherein n is an integer in the range of from 3 to 5, and wherein each R represents a lower alkoxy group containing from 1 to 6 carbon atoms.